Atai Life Sciences NV 8-K filings

Atai Beckley N.V. filed a prospectus supplement to register common shares related to its acquisition of Beckley Psytech Limited, fulfilling contractual rights.

AtaiBeckley announced Q3 2025 financial results, highlighted by FDA Breakthrough Therapy designation for BPL-003 and a strengthened balance sheet extending operations into 2029.

Atai Beckley N.V. filed a prospectus supplement to register 5.3 million common shares for resale by existing securityholders, fulfilling prior acquisition-related registration rights.

Atai Life Sciences and Beckley Psytech successfully completed their strategic combination, forming AtaiBeckley, a clinical-stage biopharmaceutical company focused on mental health treatments.

ATAI Life Sciences shareholders approved the acquisition of Beckley Psytech, a redomiciliation to Delaware, and key director appointments at an extraordinary general meeting.

ATAI Life Sciences N.V. has amended its Share Purchase Agreement with Beckley Psytech Limited, reducing the number of shares issued to Beckley Psytech shareholders and allocating shares to Cantor Fitzgerald & Co. for advisory services.

ATAI Life Sciences successfully closed its public offering, raising approximately $149.5 million to fund its clinical pipeline and extend its cash runway into 2029.

ATAI Life Sciences N.V. announced the pricing of a public offering of 23,725,000 common shares at $5.48 per share, aiming to raise approximately $121.2 million in net proceeds to fund clinical development and operations.

ATAI Life Sciences and Beckley Psytech announced that the U.S. FDA granted Breakthrough Therapy Designation to BPL-003 for treatment-resistant depression, signaling potential for expedited development.

ATAI Life Sciences is progressing with its acquisition of Beckley Psytech, which reported increased losses but positive Phase 2b results for BPL-003 and secured a $10 million loan from ATAI.

ATAI Life Sciences N.V. filed pro forma financial information and Beckley Psytech's audited financials in connection with its planned acquisition, expected to close in Q4 2025.

ATAI Life Sciences and Beckley Psytech announced positive Phase 2a data for BPL-003, demonstrating improved outcomes with a two-dose regimen in treatment-resistant depression.

ATAI Life Sciences announced positive Phase 2b results for BPL-003 in treatment-resistant depression, reduced net loss, and a strategic merger with Beckley Psytech.

ATAI Life Sciences N.V. announced a $50 million private placement financing and the achievement of primary and key secondary endpoints in Beckley Psytech's Phase 2b clinical trial for BPL-003 in treatment-resistant depression, paving the way for a strategic combination.

ATAI Life Sciences announced a definitive agreement to acquire Beckley Psytech in an all-share transaction, creating a market-leading mental health company with a synergistic pipeline and a concurrent $30 million private placement.

atai Life Sciences N.V. held its annual general meeting on May 15, 2025, where shareholders approved key proposals including director appointments and amendments to the company's articles of association.

ATAI Life Sciences announces its Q1 2025 financial results, highlighting clinical progress and a cash runway expected to extend into 2027.

atai Life Sciences N.V. fully repaid its $21.8 million loan under the Hercules Loan Agreement, terminating the agreement and associated liens.

Atai Life Sciences finalizes separation agreement with Sahil Kirpekar, former Chief Business Officer, and enters into a consulting agreement for transitional business development support.

Atai Life Sciences N.V. announces a $5 million investment in Bitcoin as part of its treasury reserve diversification strategy.

ATAI Life Sciences reports its Q4 and full year 2024 financial results, highlighting clinical trial progress and a strengthened financial position extending into 2027.

atai Life Sciences has priced a public offering of 26,190,477 common shares at $2.10 per share, expecting gross proceeds of approximately $55 million.

Michael Auerbach resigned from the supervisory board of Atai Life Sciences, reducing the board size from seven to six directors.

atai Life Sciences has announced key leadership appointments, including a new CEO, CMO, CSO, and COO, as it progresses its clinical trials for novel psychedelic therapeutics.

atai Life Sciences reported its Q3 2024 financial results and provided updates on its clinical programs, including the expected initiation of Phase 2 trials for VLS-01 and EMP-01 by year-end 2024.

atai Life Sciences N.V. has acquired IntelGenx Corp. through a credit bid, discharging its senior secured debt in exchange for shares.

ATAI Life Sciences has entered into a third amendment to its loan agreement, securing an additional $5 million and extending the availability of further tranches.

atai Life Sciences reported positive Phase 1b results for VLS-01 and announced Phase 2 study initiations for VLS-01 and EMP-01, while also providing a financial update for the second quarter of 2024.

atai Life Sciences released an investor presentation detailing its diverse portfolio of psychedelic and non-psychedelic drug development programs and strategic investments, along with its financial outlook.

atai Life Sciences announced the appointment of two new independent directors to its supervisory board and the resignation of Jason Camm.